FYARRO vs TASIGNA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. FYARRO and TASIGNA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	FYARRO	TASIGNA
Rating	New	70/100
Pharmacy pays	~$48.61 /30	—
Type	RX	RX
Active ingredient	SIROLIMUS	NILOTINIB HYDROCHLORIDE
Manufacturer	Aadi	Novartis
Dosage forms	Injectable	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

fyarro tasigna

Rating

New

70/100

Pharmacy pays

~$48.61 /30

—

Type

Active ingredient

SIROLIMUS

NILOTINIB HYDROCHLORIDE

Manufacturer

Aadi

Novartis

Dosage forms

Injectable

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

Frequently asked questions

What is the difference between Fyarro and Tasigna?

Fyarro contains Sirolimus, while Tasigna contains Nilotinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.